Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies
Lario Therapeutics awarded $2.4m by The Michael J. Fox Foundation and Wellcome to expand neuronal calcium channel platform across CNS disorders
Edinburgh, UK – 19 February 2026 – Lario Therapeutics (“Lario” or the “Company”), a biopharmaceutical company developing first-in-class precision medicines for epileptic and neurological disorders,
Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board
HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in Huntington’s disease Clinical Advisory Board
NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer
Boston, MA, – NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic
EPIDAREX CAPITAL ANNOUNCES FIRST CLOSE OF FUND IV, SECURING $145 MILLION TO BUILD NEXT WAVE OF LIFE SCIENCE START-UPS
Edinburgh, UK and Bethesda, MD, USA, 27 January 2026 – Epidarex Capital (“Epidarex”), a transatlantic life science venture firm, today announces the first close of
NodThera Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Boston, MA – NodThera, a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases through selective NLRP3 inhibition, today announced
Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering
Enables in vivo delivery of LEU011 harnessing the VivoCell PlatformTM London, UK and Chicago, IL – 15 December 2025 – Leucid Bio (“Leucid” or the
Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours
London, UK – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using its proprietary lateral